HighTower Advisors
LGND icon

HighTower Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

HighTower Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-641
Closed -$11K – 2621
2020
Q2 		$11K Buy
+641
New +$40.6K ﹤0.01% 2305

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

HighTower Advisors's LGND Position: Q1 2026 in Review

HighTower Advisors increased its Ligand Pharmaceuticals (LGND) stake by 68% in Q1 2026, buying an estimated $894K and bringing the position to 11,133 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1651.

HighTower Advisors first reported a position in LGND in Q3 2017 and has held it in 25 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • HighTower Advisors held 11,133 shares of Ligand Pharmaceuticals worth $2.22M as of Q1 2026.
  • HighTower Advisors bought 4,517 Ligand Pharmaceuticals shares in Q1 2026, an estimated $894K.
  • Ligand Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #1651 holding.
  • HighTower Advisors first reported a position in Ligand Pharmaceuticals in Q3 2017 and has held it in 25 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.